Zeiher Bernhardt G 4

What Happened
Bernhardt G. Zeiher, a director of Entrada Therapeutics (TRDA), purchased 5,000 shares in open-market transactions on 2026-05-20. The Form 4 reports a weighted-average price of $5.86 per share for a total reported outlay of $29,316. This was a purchase (insider buy), not a sale.

Key Details

• Transaction date: 2026-05-20; Form 4 filed: 2026-05-21 (filed within the standard two-business-day reporting window).
• Price reported (weighted average): $5.86 per share; total reported value: $29,316.
• Footnote F1: The $5.86 is a weighted average; the shares were bought in multiple trades at prices ranging from $5.86 to $6.00. The reporting person can provide a breakdown on request.
• Footnote F2: The reporting person disclaims beneficial ownership except to the extent of any pecuniary interest; this filing should not be interpreted as an admission of beneficial ownership under Section 16.
• Shares owned after the transaction: not disclosed in the provided Form 4.

Context
This was an open-market purchase (transaction code P) executed across multiple trades. Purchases by directors can be of interest to retail investors because they show the insider putting personal funds into the stock; this particular buy was relatively small (~$29k). The filing appears timely and includes a note that the reported price is a weighted average across several trades.